QDEL QuidelOrtho Corp
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1906324 · Fiscal year ends 01/01
Financial factors as of 2026-09-27 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.5%
TTM net income YoY68.7%
TTM EPS YoY69.0%
Revenue 3-yr CAGR-6.0%
Net income 3-yr CAGR—
Margins
Gross margin44.2%
Operating margin-4.9%
Net margin-14.2%
FCF margin-4.5%
EBITDA margin12.9%
Returns
ROE-19.3%
ROA-6.4%
ROIC (approx.)-2.2%
Asset turnover0.45x
Leverage & solvency
Liabilities / assets69.0%
Debt / equity1.64x
Current ratio1.36x
Interest coverage-0.60x
Cash quality & payout
Operating cash flow / net income-0.02x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue4.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-28 | FY20242024-12-29 | FY20232023-12-31 | FY20222023-01-01 | FY20222022-01-02 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.73B | $2.78B | $3.00B | $3.27B | $1.70B |
| Cost of revenue | $1.46B | $1.50B | $1.50B | $1.33B | $420.30M |
| Gross profit | $1.27B | $1.29B | $1.50B | $1.94B | $1.28B |
| R&D expense | $186.20M | $218.70M | $245.00M | $187.90M | $95.70M |
| SG&A expense | $746.30M | $766.80M | $763.20M | $621.00M | $239.60M |
| Operating income | -$919.20M | -$1.96B | $139.10M | $843.70M | $906.00M |
| Interest expense | $177.60M | $163.50M | $147.60M | $75.70M | — |
| Pretax income | -$1.11B | -$2.13B | -$29.10M | $735.90M | $900.30M |
| Income tax | $24.10M | -$79.50M | -$19.00M | $187.20M | $196.10M |
| Net income | -$1.13B | -$2.05B | -$10.10M | $548.70M | $704.20M |
| EBITDA | -$477.20M | -$1.51B | $596.30M | $1.13B | $958.70M |
| EPS (basic) | -16.69 | -30.54 | -0.15 | 9.66 | 16.74 |
| EPS (diluted) | -16.69 | -30.54 | -0.15 | 9.56 | 16.43 |
| Weighted avg. shares (diluted) | 67.80M | 67.20M | 66.80M | 57.40M | 42.90M |
| Banking | |||||
| Net interest income | — | -$163.50M | -$147.60M | -$75.70M | -$5.80M |
| Balance sheet | |||||
| Cash & equivalents | $169.80M | $98.50M | $119.50M | $293.90M | $802.80M |
| Short-term investments | — | $0 | $48.40M | $52.10M | $25.70M |
| Receivables | $417.00M | $282.40M | $303.30M | $453.90M | $378.00M |
| Inventory | $577.60M | $533.70M | $577.80M | $524.10M | $198.80M |
| Current assets | $1.45B | $1.22B | $1.31B | $1.58B | $1.44B |
| PP&E, net | $1.36B | $1.38B | $1.44B | $1.34B | $349.20M |
| Goodwill | $0 | $649.50M | $2.49B | $2.48B | $337.00M |
| Intangibles | $2.56B | $2.74B | $2.93B | $3.12B | $98.70M |
| Total assets | $5.77B | $6.42B | $8.56B | $8.86B | $2.43B |
| Current liabilities | $966.10M | $998.80M | $833.80M | $1.01B | $323.50M |
| Short-term debt | $178.30M | $341.80M | $139.80M | $207.50M | $300,000 |
| Long-term debt | $2.47B | $2.14B | $2.27B | $2.43B | $700,000 |
| Total debt | $2.65B | $2.48B | $2.41B | $2.64B | $1.00M |
| Total liabilities | $3.85B | $3.44B | $3.56B | $3.92B | $501.00M |
| Shareholders' equity | $1.92B | $2.98B | $5.01B | $4.93B | $1.93B |
| Net debt | $2.48B | $2.38B | $2.30B | $2.34B | -$801.80M |
| Shares outstanding | 67.90M | 67.30M | 66.70M | 66.40M | 41.70M |
| Cash flow statement | |||||
| Operating cash flow | $105.20M | $83.00M | $280.20M | $885.30M | $805.90M |
| Capital expenditure | $188.20M | $195.10M | $209.30M | $140.90M | $292.80M |
| Free cash flow | -$83.00M | -$112.10M | $70.90M | $744.40M | $513.10M |
| Investing cash flow | -$192.70M | -$149.90M | -$187.60M | -$1.64B | -$319.50M |
| Financing cash flow | $155.80M | $48.80M | -$265.80M | $252.00M | -$173.10M |
| Depreciation & amortization | $442.00M | $453.40M | $457.20M | $283.60M | $52.70M |
| Stock-based compensation | $45.90M | $42.10M | $51.60M | $48.40M | $25.40M |
| Share buybacks | $0 | $0 | $7.20M | $74.30M | $103.50M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.